Aptamer is a leader in the provision of aptamer discovery services and the development of aptamer-based reagents. The Group solves intractable problems for biotech and big pharma by developing molecular binders called aptamers, as an alternative to antibodies which fail to perform 50% – 60% of the time. Led by an experienced team, Aptamer has developed novel, proprietary aptamer technology, known as Optimer® binders, which offer further performance and commercial benefits in addition to those of standard aptamers.
Aptamer operates across three life science sectors: custom services (research and bioprocessing tools), diagnostics and therapeutics. The Group has an existing blue-chip customer base and has supplied or collaborated with 75% of the global top 20 pharmaceutical companies.
Aptamers are a disruptive technology and next generation affinity ligand in the well-established global antibody market. The aptamer market is set to expand rapidly over the next five to 10 years into a multi-billion-dollar world-wide market and is forecast to grow at 18-28% per annum.
